1 unchanged sentence
Evaluation of disclosure controls and procedures.
−Removed: Our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal accounting officer) have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this annual report on Form 10-K.
+Added: Under the supervision and with the participation of our principal executive and financial officer, our management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, prior to the filing of this annual report on Form 10-K.
Based on that evaluation, they have concluded that, as of the end of the period covered by this annual report on Form 10-K, our disclosure controls and procedures were, in design and operation, effective at a reasonable assurance level.
4 unchanged sentences
Changes in internal control over financial reporting.
−Removed: There have not been any changes in our internal control over financial reporting during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
+Added: There have not been any changes in our internal control over financial reporting during the year ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent limitation on the effectiveness of internal control.
44 unchanged sentences
3.1 Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2014
−Removed: 3.2 Amended and Restated Bylaws of Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 13, 2020
+Added: 3.2 Amended and Restated Bylaws of Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on J anuary 23, 2023
3.3 Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Stock, filed August 8, 2019—Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August 12, 2019
15 unchanged sentences
3, LLC —Incorporated by reference to Exhibit 10.8 to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 12, 2020
−Removed: 10.4+ Joint Canadian Stock Option Plan—Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1 (File No.
−Removed: 333-193615) filed with the Securities and Exchange Commission on January 28, 2014
−Removed: 10.5+ Forms of Option Agreement for Registrant’s Joint Canadian Stock Option Plan—Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 (File No.
−Removed: 333-193615) filed with the Securities and Exchange Commission on January 28, 2014
10.4+ Neoleukin Therapeutics, Inc.
9 unchanged sentences
Number Description
−Removed: 10.11 Lease Agreement, dated February 5, 2016, by and between Aquinox Pharmaceuticals (Canada) Inc.
−Removed: and 560677 B.C.
−Removed: Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2016
−Removed: 10.12+ Executive Employment Agreement, dated March 16, 2020, Neoleukin Therapeutics, Inc.
−Removed: and Robert Ho—Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission on May 6, 2020.
10.10+ Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G.
5 unchanged sentences
10.13 Amendment No.
−Removed: 1 to Exclusive Start-Up License Agreemen t, dated July 24, 2020, by a nd between the University of Washington and Neoleukin Therapeutics, Inc.
−Removed: —Incorporated by reference to Exhibit 10.
−Removed: 21 to our Annual Report on Form 10-K for the year ended December 31, 20 20 filed with the Securities and Exchange Commission on March 25, 2021
+Added: 1 to Exclusive Start-Up License Agreemen t, dated July 24, 2020, by a nd between the University of Washington and Neoleukin Therapeutics, Inc.—Incorporated by reference to Exhibit 10.21 to our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 25, 2021
10.14 First Amendment to Lease, dated November 5, 2020, by and between Neoleukin Therapeutics, Inc.
6 unchanged sentences
2 to Exclusive Start-Up License Agreement, dated December 15, 2021, by and between the University of Washington and Neoleukin Therapeutics, Inc.
+Added: – Incorporated by reference to our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 1, 2022.
10.17 ATM Equity Offering Sales Agreement, dated November 4, 2021, by and between Neoleukin Therapeutics, Inc.
2 unchanged sentences
10.18+ Employment Agreement, dated April 14, 2021, by and between Neoleukin Therapeutics, Inc.
−Removed: and Priti Patel.
+Added: and Priti Patel—Incorporated by reference to Exhibit 10.21 to our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 1, 2022.
+Added: 10.19+ Employment Agreement, dated March 4, 2022, by and between Neoleukin Therapeutics, Inc.
+Added: and Donna Cochener.
21.1 List of subsidiaries of the Registrant
23.1 Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
−Removed: 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
−Removed: 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
−Removed: 32.1# Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.
+Added: 31.1 Certification of Chief Executive Officer (Principal Executive and Financial Officer) pursuant to Rule 13a-14(a).
+Added: 32.1# Certification of Chief Executive Officer (Principal Executive and Fi nancial Officer) pursuant to 18 U.S.C.
Section 1350.
5 unchanged sentences
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+ Indicates a management contract or compensatory plan.
8 unchanged sentences
President & Chief Executive Officer
−Removed: (Principal Executive Officer)
+Added: (Principal Executive and Financial Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
1 unchanged sentence
/s/ Jonathan G.
−Removed: Drachman Director, President & Chief Executive Officer
−Removed: (Principal Executive Officer) March 1, 2022
−Removed: /s/ Robert Ho Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer) March 1, 2022
+Added: Drachman President & Chief Executive Officer
+Added: (Principal Executive and Financial Officer) March 20, 2023
+Added: /s/ Sean Smith Vice President, Finance
+Added: (Principal Accounting Officer) March 20, 2023
/s/ Martin Babler Director March 20, 2023
4 unchanged sentences
Sarah Noonberg
+Added: /s/ Rohan Palekar Director March 20, 2023
+Added: Rohan Palekar
/s/ Todd Simpson Director March 20, 2023
−Removed: Williams Director March 1, 2022
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.